Molecular simulations revealed that single amino acid mutations at position 24 of an LL-37 antimicrobial peptide fragment dramatically changed its aggregation behavior, with charged substitutions either blocking or enhancing clumping that is essential for bacterial killing.
One amino acid = opposite effectsChanging position 24 to lysine (I24K) nearly eliminated aggregation, while aspartate (I24D) strongly enhanced it — showing how single mutations can dramatically alter antimicrobial peptide assembly
What the researchers found
All-atom molecular dynamics simulations of the wild-type hLL-37₁₇₋₂₉ peptide and five I24 mutants revealed a biphasic aggregation process: rapid small oligomer formation via hydrophobic collapse, followed by structural reorganization.
Mutant-specific behaviors were striking: I24D (aspartate) and I24Q (glutamine) were strongly aggregation-prone, I24K (lysine) was aggregation-resistant with strong solvation and minimal clumping, and I24A (alanine) and I24S (serine) showed intermediate behavior. Mutations destabilized the amphipathic α-helix critical for membrane activity, especially charged variants, with helix unfolding concentrated near the peptide termini. Aggregate morphology remained predominantly fibrillar across all systems, but internal order varied. Aggregation was governed by a balance between electrostatic and van der Waals forces, with each mutation shifting this balance differently.
Why it matters
Antimicrobial peptides are being developed as alternatives to antibiotics, but designing effective versions requires understanding exactly how they work at the molecular level. Since LL-37's bacteria-killing ability depends on aggregation, knowing which amino acid changes enhance or reduce clumping provides a blueprint for engineering more potent antimicrobial peptides. This is especially valuable as antibiotic resistance continues to grow worldwide.
How the study worked
Researchers performed all-atom molecular dynamics (MD) simulations under constant pressure and temperature (NPT) conditions. They modeled the wild-type hLL-37₁₇₋₂₉ peptide and five point mutants (I24A, I24D, I24K, I24Q, I24S) in explicit solvent. They analyzed aggregation kinetics, secondary structure stability, transition network pathways, aggregate morphology, energetic contributions, preferential interaction parameters, and hydrogen bonding patterns to comprehensively characterize how each mutation altered aggregation behavior.
What this study cannot tell us
This is a purely computational study using molecular dynamics simulations. While the simulations are detailed, they model peptide behavior in water rather than at actual bacterial membrane surfaces, where aggregation occurs in nature. The simulation timescales may not capture all relevant slow conformational changes. Experimental validation of the predicted aggregation behaviors has not been performed. The simulations focused on aggregation propensity but did not directly model antimicrobial activity.
How to read the evidence
This is a computational study using molecular dynamics simulations. While it provides detailed mechanistic predictions, all findings are theoretical and require experimental validation. It represents hypothesis-generating evidence for rational peptide design.
When this study was published
Published in 2025, this study uses current computational methods to address a fundamental question in antimicrobial peptide biology. The findings are directly applicable to ongoing efforts to design shorter, more stable LL-37 derivatives.
The bigger picture
This study sits at the intersection of computational biology and peptide drug design. LL-37 is the only human cathelicidin and one of the most-studied antimicrobial peptides, but its clinical use is limited by its size and instability. Understanding the structure-aggregation-function relationship of its shorter fragments could lead to minimal, optimized peptide drugs that retain LL-37's killing power in a smaller, more stable package. The computational approach used here can screen many variants rapidly before expensive lab synthesis.
Questions still open
- Do the computationally predicted aggregation differences translate to measurable changes in antimicrobial potency in laboratory experiments?
- Could the aggregation-resistant I24K variant be useful in contexts where aggregation causes unwanted toxicity to human cells?
- Would combining position 24 mutations with changes at other sites produce synergistic improvements in antimicrobial peptide design?
Common questions
Why does LL-37 need to clump together to kill bacteria?
How can computer simulations help design better antimicrobial peptides?
Read the original research
Effect of Point Mutations on the Aggregation Tendency of the Antimicrobial Fragment Peptide hLL-3717-29.
The journal of physical chemistry. B, 129(44), 11474-11489
Citation
Mitra, Aritra; Paul, Sandip. (2025). Effect of Point Mutations on the Aggregation Tendency of the Antimicrobial Fragment Peptide hLL-3717-29.. The journal of physical chemistry. B, 129(44), 11474-11489. https://doi.org/10.1021/acs.jpcb.5c05943